Advancing novel CNS therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain
View Product PipelineAbout
We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders.
Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
Recent Updates:
On September 6, 2018, we hosted a webcast providing an overview of the addition of XEN496 to our clinical pipeline.
Read MoreNews
Xenon to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting
November 30, 2018
Xenon to Present at the Stifel 2018 Healthcare Conference
November 7, 2018
Xenon Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 6, 2018
Xenon to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
October 30, 2018
Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares
September 17, 2018
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
